Durability parameters of reinforced recycled aggregate concrete: Case study

Recycled concrete aggregate (RA) from pavement demolition was used to make concrete. Ten concrete mixtures with different replacement percentages of RA (coarse and fine) were made. The corrosion rate of steel and the electrical resistivity of concrete were determined on reinforced concrete specimens subjected to wetting-drying cycles (3.5% solution of NaCl). Corrosion rate was determined using the electrochemical technique of linear polarization resistance, while the electrical resistivity was measured by electrochemical impedance spectroscopy. The results show that the use of RA introduces more interfaces in concrete, which accelerates the steel corrosion process because the porosity increases and the electrical resistivity decreases. However, steel corrosion and the electrical resistivity in concrete are not significantly influenced by replacing a maximum 30% of coarse aggregate or 20% of fine aggregate with RA.Peer ReviewedPreprin

Adaptability of the threatened jaguarundi (Herpailurus yagouaroundi Schereber, 1777) to human-altered environments in San Luis Potosí, Mexico

La persistencia y recuperación de especies raras en regiones en desarrollo con áreas protegidas limitadas depende de su adaptabilidad a los hábitats alterados por el hombre. El jaguarundi (Herpailurus yagouaroundi) está clasificado como amenazado en México, y el conocimiento de su distribución y su correlación con el ambiente es necesario para los esfuerzos de recuperación informados. Sin embargo, poco se sabe sobre el hábitat o la distribución de jaguarundi en el interior de México, incluido el estado de San Luis Potosí (SLP). Realizamos 96 entrevistas semiestructuradas en comunidades, ejidos y ranchos a lo largo de SLP para obtener registros de la presencia de jaguarundi e identificar correlaciones ambientales y atributos de sitios asociados con su ocurrencia. Evaluamos las entrevistas utilizando criterios analíticos de credibilidad y recopilamos información sobre hábitats de 50 eventos confiables de tres de las cuatro regiones geográficas de SLP. En comparación con el paisaje de SLP, las ocurrencias de jaguarundi se ubicaron más cerca del agua, más cerca de las carreteras, a bajas elevaciones, marginalmente más cerca de las comunidades, y en áreas con mayor borde total, densidad de bordes y número de parches de paisaje. El jaguarundi mostró preferencia por los mosaicos de bosques tropicales, agrícolas, de pastizales y urbanos (es decir, cualquier comunidad). Coberturas de escondite relativamente denso o de emboscada generalmente estaban presentes en los sitios de ocurrencia. Colectivamente, el modelo de máxima entropía y el modelo de regresión logística predijeron una probabilidad similar y alta de presencia de jaguarundi en regiones caracterizadas por mosaicos de bosques tropicales, agricultura, pastizales o tipos de cobertura urbana <500 m en elevación y <2 km desde carreteras. Estos paisajes de mosaicos tendían a estar relativamente cerca de comunidades de densidades moderadas de población y agua, y generalmente soportan densidades de presas pequeñas más altas que las áreas menos fragmentadas. Los jaguarundi se adaptaron al menos a las perturbaciones ligeras y moderadas relacionadas con los seres humanos, y pueden verse beneficiados por el aumento de los mosaicos de borde y hábitat.Persistence and recovery of rare species in developing regions with limited protected areas depends upon their adaptability to human-altered habitats. The jaguarundi (Herpailurus yagouaroundi) is classed as threatened in Mexico, and knowledge of its distribution and environmental correlates is necessary for informed recovery efforts. However, little is known of jaguarundi habitat or distribution in interior Mexico, including the state of San Luis Potosí (SLP). We conducted 96 semi-structured interviews around communities, ejidos, and ranches throughout SLP to obtain records of jaguarundi presence and identify environmental correlates and site attributes associated with its occurrence. We evaluated interviews using analytical criteria of credibility, and collected habitat information from 50 reliable occurrences from three of the four geographic regions of SLP. Compared to the SLP landscape, jaguarundi occurrences were located closer to water, closer to roads, at lower elevation, marginally closer to communities, and in areas with greater total edge, edge density, and number of landscape patches. Jaguarundi showed preference for mosaics of tropical forest, agricultural, grassland, and urban (i.e., any community) cover types. Relatively dense hiding or ambush cover was usually present at occurrence sites. Collectively, maximum entropy modeling and logistic regression modeling predicted similar and high likelihood of jaguarundi presence in regions characterized by mosaics of tropical forest, agriculture, grassland, or urban cover types <500 m in elevation and <2 km from roads. These mosaic landscapes tended to be relatively close to communities of moderate population densities and water, and typically support higher small prey densities than less fragmented areas. Jaguarundi were adaptable to at least light–moderate human-related disturbance, and may be benefitted by it because of increased edge and habitat mosaics

Hsp72 (HSPA1A) Prevents Human Islet Amyloid Polypeptide Aggregation and Toxicity: A New Approach for Type 2 Diabetes Treatment

Type 2 diabetes is a growing public health concern and accounts for approximately 90% of all the cases of diabetes. Besides insulin resistance, type 2 diabetes is characterized by a deficit in β-cell mass as a result of misfolded human islet amyloid polypeptide (h-IAPP) which forms toxic aggregates that destroy pancreatic β-cells. Heat shock proteins (HSP) play an important role in combating the unwanted self-association of unfolded proteins. We hypothesized that Hsp72 (HSPA1A) prevents h-IAPP aggregation and toxicity. In this study, we demonstrated that thermal stress significantly up-regulates the intracellular expression of Hsp72, and prevents h-IAPP toxicity against pancreatic β-cells. Moreover, Hsp72 (HSPA1A) overexpression in pancreatic β-cells ameliorates h-IAPP toxicity. To test the hypothesis that Hsp72 (HSPA1A) prevents aggregation and fibril formation, we established a novel C. elegans model that expresses the highly amyloidogenic human pro-IAPP (h-proIAPP) that is implicated in amyloid formation and β-cell toxicity. We demonstrated that h-proIAPP expression in body-wall muscles, pharynx and neurons adversely affects C. elegans development. In addition, we demonstrated that h-proIAPP forms insoluble aggregates and that the co-expression of h-Hsp72 in our h-proIAPP C. elegans model, increases h-proIAPP solubility. Furthermore, treatment of transgenic h-proIAPP C. elegans with ADAPT-232, known to induce the expression and release of Hsp72 (HSPA1A), significantly improved the growth retardation phenotype of transgenic worms. Taken together, this study identifies Hsp72 (HSPA1A) as a potential treatment to prevent β-cell mass decline in type 2 diabetic patients and establishes for the first time a novel in vivo model that can be used to select compounds that attenuate h-proIAPP aggregation and toxicity

Los procesos corpoemocionales en los estudios de género y sexualidades

En esta obra se piensa al cuerpo en su vínculo con las emociones y con su correlato social, en tanto que profundiza en la utilización de estas como un lenguaje político y no solo como un asunto exclusivo de la esfera de la intimidad. En esta obra colectiva, dirigida a investigadores, especialistas y profesionales relacionados con la sexualidad, las autoras aportan lecturas que develan la importancia de abordar la vida emocional en los estudios de género, sociológicos y de la cultura. Profundizan en temas como la historia de la salud mental, el amor materno como construcción social, la violencia sexual en los espacios públicos o los derechos de la comunidad LGBTTTI.ITESO, A.C

High serum levels of transforming growth factor β1 are associated with increased cortical thickness in cingulate and right frontal areas in healthy subjects

ABSTRACT

Regional cortical volumes and congenital heart disease: a MRI study in 22q11.2 deletion syndrome

Children with congenital heart disease (CHD) who survive surgery often present impaired neurodevelopment and qualitative brain anomalies. However, the impact of CHD on total or regional brain volumes only received little attention. We address this question in a sample of patients with 22q11.2 deletion syndrome (22q11DS), a neurogenetic condition frequently associated with CHD. Sixty-one children, adolescents, and young adults with confirmed 22q11.2 deletion were included, as well as 80 healthy participants matched for age and gender. Subsequent subdivision of the patients group according to CHD yielded a subgroup of 27 patients with normal cardiac status and a subgroup of 26 patients who underwent cardiac surgery during their first years of life (eight patients with unclear status were excluded). Regional cortical volumes were extracted using an automated method and the association between regional cortical volumes, and CHD was examined within a three-condition fixed factor. Robust protection against type I error used Bonferroni correction. Smaller total cerebral volumes were observed in patients with CHD compared to both patients without CHD and controls. The pattern of bilateral regional reductions associated with CHD encompassed the superior parietal region, the precuneus, the fusiform gyrus, and the anterior cingulate cortex. Within patients, a significant reduction in the left parahippocampal, the right middle temporal, and the left superior frontal gyri was associated with CHD. The present results of global and regional volumetric reductions suggest a role for disturbed hemodynamic in the pathophysiology of brain alterations in patients with neurodevelopmental disease and cardiac malformations

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington\u27s Disease Patients-A Randomized Phase 2 Clinical Trial.

SRX246 is a vasopressin (AVP) 1a receptor antagonist that crosses the blood-brain barrier. It reduced impulsive aggression, fear, depression and anxiety in animal models, blocked the actions of intranasal AVP on aggression/fear circuits in an experimental medicine fMRI study and demonstrated excellent safety in Phase 1 multiple-ascending dose clinical trials. The present study was a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12-week, dose escalation study of SRX246 in early symptomatic Huntington\u27s disease (HD) patients with irritability. Our goal was to determine whether SRX246 was safe and well tolerated in these HD patients given its potential use for the treatment of problematic neuropsychiatric symptoms. Participants were randomized to receive placebo or to escalate to 120 mg twice daily or 160 mg twice daily doses of SRX246. Assessments included standard safety tests, the Unified Huntington\u27s Disease Rating Scale (UHDRS), and exploratory measures of problem behaviors. The groups had comparable demographics, features of HD and baseline irritability. Eighty-two out of 106 subjects randomized completed the trial on their assigned dose of drug. One-sided exact-method confidence interval tests were used to reject the null hypothesis of inferior tolerability or safety for each dose group vs. placebo. Apathy and suicidality were not affected by SRX246. Most adverse events in the active arms were considered unlikely to be related to SRX246. The compound was safe and well tolerated in HD patients and can be moved forward as a candidate to treat irritability and aggression

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362